Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial

European Urology

Volumn 51, Issue 3, 2007, Pages 739-748

  Droz, Jean Pierre ^a   Kramar, Andrew ^b   Biron, Pierre ^a   Pico, José Luis ^c   Kerbrat, Pierre ^d   Pény, Jean ^e   Curé, Hervé ^f   Chevreau, Christine ^g   Théodore, Christine ^c   Bouzy, Jeannine ^c   Culine, Stéphane ^b  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f CENTRE JEAN PERRIN   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Advanced disease; Germ cell tumours; High dose chemotherapy; Randomised trial

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MESNA; VINBLASTINE;

ADULT; ALOPECIA; ARTICLE; BACTEREMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEVER; FOLLOW UP; HEPATIC CYTOLYSIS; HEPATIC RETENTION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TREATMENT FAILURE;

EID: 33846259793     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.10.035     Document Type: Article

References (39)

1. Einhorn L.H. Treatment of testicular cancer: a new and improved model. J Clin Oncol 8 (1990) 1777-1781
2. Einhorn L.H., and Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87 (1977) 293-298
3. Ozols R.F., Deisseroth A.B., Javadpour N., Barlock A., Messerschmidt G.L., and Young R.C. Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen. Cancer 51 (1983) 1803-1807
4. Ozols R.F., Ihde D.C., Linehan W.M., Jacob J., Ostchega Y., and Young R.C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6 (1988) 1031-1040
5. Droz J.P., Pico J.L., Hayat M., Kamioner D., Gouyette A., and Beaujean F. A phase I-II trial of intensive chemotherapy with autologous bone-marrow transplantation in metastatic malignant germ cell tumors of the testis. Prog Clin Biol Res 203 (1985) 449-450
6. Droz J.P., Pico J.L., Ghosn M., et al. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer 27 (1991) 831-835
7. Droz J.P., Pico J.L., Ghosn M., et al. High complete remission and survival rates in poor prognosis non seminomatous germ cell tumors with high dose chemotherapy and autologous bone marrow transplantation. Proc Am Soc Clin Oncol 8 (1989) 130
8. Droz J.P., Pico J.L., Ghosn M., et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer 79 (1992) 497-507
9. Chevreau C., Droz J.P., Pico J., et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Eur Urol 23 (1993) 213-218
10. Droz J.P., Kramar A., Ghosn M., et al. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 62 (1988) 564-568
11. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
12. Moran-Ribon A., Droz J.P., Kattan J., et al. Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases. Support Care Cancer 2 (1994) 253-258
13. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 16 (1998) 1244-1247
14. Droz J.P., Pico J.L., Biron P., et al. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non seminomatous germ cell tumors: preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11 (1992) 197
15. Buckner C.D., Clift R.A., Fefer A., et al. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep 58 (1974) 709-714
16. Postmus P.E., de Vries E.G., De Vries-Hospers H.G., et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study. Eur J Cancer Clin Oncol 20 (1984) 777-782
17. Postmus P.E., Mulder N.H., Sleijfer D.T., Meinesz A.F., Vriesendorp R., and de Vries E.G. High-dose etoposide for refractory malignancies: a phase I study. Cancer Treat Rep 68 (1984) 1471-1474
18. Norton L., and Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 70 (1986) 163-169
19. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., and Loehrer P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 (1987) 1435-1440
20. Nichols C.R., Williams S.D., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9 (1991) 1163-1172
21. Samson M.K., Rivkin S.E., Jones S.E., et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53 (1984) 1029-1035
22. de Wit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 (1997) 1837-1843
23. Toner G.C., Stockler M.R., Boyer M.J., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357 (2001) 739-745
24. Loehrer Sr. P.J., Williams S.D., and Einhorn L.H. Testicular cancer: the quest continues. J Natl Cancer Inst 80 (1988) 1373-1382
25. Skipper H.E. Dose intensity versus total dose of chemotherapy: an experimental basis. Important Adv Oncol 5 (1990) 43-64
26. O'Reilly S.M., Rustin G.J., Smith D.B., and Newlands E.S. Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours. Ann Oncol 3 (1992) 163-164
27. Nichols C.R., Tricot G., Williams S.D., et al. Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7 (1989) 932-939
28. Motzer R.J., Gulati S.C., Tong W.P., et al. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53 (1993) 3730-3735
29. Ibrahim A., Zambon E., Bourhis J.H., et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 29A (1993) 1398-1403
30. Siegert W., Beyer J., Strohscheer I., et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12 (1994) 1223-1231
31. Lotz J.P., Machover D., Malassagne B., et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9 (1991) 1860-1870
32. Motzer R.J., Mazumdar M., Gulati S.C., et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85 (1993) 1828-1835
33. Motzer R.J., Mazumdar M., Bajorin D.F., Bosl G.J., Lyn P., and Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15 (1997) 2546-2552
34. Bajorin D.F., Nichols C.R., Margolin K.A., et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors patients: a cooperative group trial by Memorial-Sloan-Kettering Cancer Center, ECOG, SWOG and CALGB. J Clin Oncol 24 (2006) 219s
35. Schmoll H.J., Kollmannsberger C., Metzner B., et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21 (2003) 4083-4091
36. Bokemeyer C., Kollmannsberger C., Meisner C., et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17 (1999) 3450-3456
37. Albers P., Albrecht W., Algaba F., et al. Guidelines on testicular cancer. Eur Urol 48 (2005) 885-894
38. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377-1399
39. Fizazi K., Culine S., Kramar A., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22 (2004) 3842-3845